← Leaderboards
Severin O Gudima
University Of Kansas Medical Center
$5,431,875
Attributed
$6,439,795
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $845.8K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,439,795 · 11
By mechanism
R01$3,132,424 · 2
R21$2,915,724 · 7
P20$391,647 · 2
Top collaborators
- Stephan Menne5 shared
- Steven A Weinman2 shared
Others in their field
Top investigators on “Hepatitis B Virus”
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$152,807,032
- Judith S. Currier · University Of California Los Angeles$150,849,200
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Sharon A Nachman · Johns Hopkins University$91,579,826
- Robert Turner Schooley · University Of Colorado Denver$44,837,839
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$44,694,148
Research focus
Hepatitis B VirusChronicLiverCellsHepatocytePrimary Carcinoma Of The Liver CellsPharmaceutical PreparationsVirusChronic Hepatitis BVirionPathogenesisGenomeEnv Gene ProductsMaintenanceAffectVirus DiseasesViralHepatitis Delta VirusAnti-Hepatitis BMutationSerumIn VitroPropertyInfection
Grant awards (25)
Influence of integrant-derived HBV RNAs encoding the envelope proteins on HBV life cycle$375,875
R01 · FY2025 · AI · contact PI
Characterization of 5'-human-HBV-3' RNA species transcribed from integrated HBV DNA$225,525
R21 · FY2025 · AI · contact PI
Influence of integrant-derived HBV RNAs encoding the envelope proteins on HBV life cycle$387,500
R01 · FY2024 · AI · contact PI
Characterization of 5'-human-HBV-3' RNA species transcribed from integrated HBV DNA$193,750
R21 · FY2024 · AI · contact PI
Influence of integrant-derived HBV RNAs encoding the envelope proteins on HBV life cycle$387,500
R01 · FY2023 · AI · contact PI
Influence of integrant-derived HBV RNAs encoding the envelope proteins on HBV life cycle$386,458
R01 · FY2022 · AI · contact PI
Regulation of HDV life cycle by the immune response to HBV infection$232,375
R21 · FY2022 · AI · contact PI
Regulation of the life cycle of HDV by the drug resistance mutations of HBV$227,000
R21 · FY2022 · AI · contact PI
Regulation of HDV life cycle by the immune response to HBV infection$192,500
R21 · FY2021 · AI · contact PI
Regulation of the life cycle of HDV by the drug resistance mutations of HBV$192,500
R21 · FY2021 · AI · contact PI
HBV RNAs produced by viral replication and derived from integrated HBV DNA as potential biomarkers predicting the efficiency of clinical response to nucleos(t)ide analogs$229,500
R21 · FY2020 · AI · contact PI
Regulation of HDV infection in humans$226,479
R21 · FY2020 · AI · contact PI
HBV RNAs produced by viral replication and derived from integrated HBV DNA as potential biomarkers predicting the efficiency of clinical response to nucleos(t)ide analogs$191,250
R21 · FY2019 · AI · contact PI
Regulation of HDV infection in humans$191,250
R21 · FY2019 · AI · contact PI
Super-infection and virus spread during chronic hepadnaviral infection$319,945
R01 · FY2016 · CA · contact PI
Super-infection and virus spread during chronic hepadnaviral infection$319,945
R01 · FY2015 · CA · contact PI
Super-infection and virus spread during chronic hepadnaviral infection$310,347
R01 · FY2014 · CA · contact PI
Persistence of hepatitis delta virus infection in absence of HBV replication$223,185
R21 · FY2014 · AI · contact PI
Super-infection and virus spread during chronic hepadnaviral infection$305,320
R01 · FY2013 · CA · contact PI
HDV spread during chronic infection as a novel target for antiviral intervention$212,910
R21 · FY2013 · AI · contact PI
Persistence of hepatitis delta virus infection in absence of HBV replication$188,750
R21 · FY2013 · AI · contact PI
Super-infection and virus spread during chronic hepadnaviral infection$339,534
R01 · FY2012 · CA · contact PI
HDV spread during chronic infection as a novel target for antiviral intervention$188,750
R21 · FY2012 · AI · contact PI
HEPATITIS B VIRUS/HEPATITIS DELTA VIRUS INFECTION, ITS RELATION TO PATHOGENESIS$276,695
P20 · FY2010 · RR · contact PI
HEPATITIS B VIRUS/HEPATITIS DELTA VIRUS INFECTION, ITS RELATION TO PATHOGENESIS$114,952
P20 · FY2009 · RR · contact PI